Equillium Inc
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as we… Read more
Equillium Inc (EQ) - Net Assets
Latest net assets as of September 2025: $30.94 Million USD
Based on the latest financial reports, Equillium Inc (EQ) has net assets worth $30.94 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($34.51 Million) and total liabilities ($3.57 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $30.94 Million |
| % of Total Assets | 89.66% |
| Annual Growth Rate | N/A |
| 5-Year Change | -72.71% |
| 10-Year Change | N/A |
| Growth Volatility | 38.18 |
Equillium Inc - Net Assets Trend (2017–2024)
This chart illustrates how Equillium Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Equillium Inc (2017–2024)
The table below shows the annual net assets of Equillium Inc from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $19.06 Million | -15.56% |
| 2023-12-31 | $22.57 Million | -29.33% |
| 2022-12-31 | $31.94 Million | -51.97% |
| 2021-12-31 | $66.50 Million | -4.79% |
| 2020-12-31 | $69.85 Million | +66.92% |
| 2019-12-31 | $41.85 Million | -35.55% |
| 2018-12-31 | $64.94 Million | +2983.33% |
| 2017-12-31 | $-2.25 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Equillium Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 19154512600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.00K | 0.02% |
| Other Comprehensive Income | $781.00K | 4.10% |
| Other Components | $212.08 Million | 1112.66% |
| Total Equity | $19.06 Million | 100.00% |
Equillium Inc Competitors by Market Cap
The table below lists competitors of Equillium Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Berjaya Land Bhd
KLSE:4219
|
$62.43 Million |
|
Upexi Inc.
NASDAQ:UPXI
|
$62.43 Million |
|
Deva Holding AS
IS:DEVA
|
$62.43 Million |
|
Yatra Online Limited
NSE:YATRA
|
$62.46 Million |
|
Eolus Vind AB Series B
LSE:0R8F
|
$62.40 Million |
|
APCB Inc
TW:6108
|
$62.40 Million |
|
Yimutian Inc. American Depositary Shares
NASDAQ:YMT
|
$62.38 Million |
|
GM Breweries Limited
NSE:GMBREW
|
$62.36 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Equillium Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 22,573,000 to 19,061,000, a change of -3,512,000 (-15.6%).
- Net loss of 8,067,000 reduced equity.
- Share repurchases of 160,000 reduced equity.
- Other comprehensive income increased equity by 641,000.
- Other factors increased equity by 4,074,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.07 Million | -42.32% |
| Share Repurchases | $160.00K | -0.84% |
| Other Comprehensive Income | $641.00K | +3.36% |
| Other Changes | $4.07 Million | +21.37% |
| Total Change | $- | -15.56% |
Book Value vs Market Value Analysis
This analysis compares Equillium Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.99x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-0.13 | $2.15 | x |
| 2018-12-31 | $5.33 | $2.15 | x |
| 2019-12-31 | $2.41 | $2.15 | x |
| 2020-12-31 | $3.43 | $2.15 | x |
| 2021-12-31 | $2.31 | $2.15 | x |
| 2022-12-31 | $0.95 | $2.15 | x |
| 2023-12-31 | $0.65 | $2.15 | x |
| 2024-12-31 | $0.54 | $2.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Equillium Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -42.32%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -19.63%
- • Asset Turnover: 1.61x
- • Equity Multiplier: 1.34x
- Recent ROE (-42.32%) is above the historical average (-59.95%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.04 Million |
| 2018 | -20.41% | 0.00% | 0.00x | 1.03x | $-19.74 Million |
| 2019 | -61.12% | 0.00% | 0.00x | 1.33x | $-29.76 Million |
| 2020 | -42.61% | 0.00% | 0.00x | 1.22x | $-36.75 Million |
| 2021 | -58.61% | 0.00% | 0.00x | 1.28x | $-45.63 Million |
| 2022 | -195.44% | -396.14% | 0.20x | 2.46x | $-65.62 Million |
| 2023 | -59.08% | -36.96% | 0.71x | 2.24x | $-15.59 Million |
| 2024 | -42.32% | -19.63% | 1.61x | 1.34x | $-9.97 Million |
Industry Comparison
This section compares Equillium Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Equillium Inc (EQ) | $30.94 Million | 0.00% | 0.12x | $62.43 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |